The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions
Hyperlipemia
Interventions
DRUG

JS002

JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.

DRUG

Placebo

JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.

Trial Locations (21)

100029

Beijing Anzhen Hospital,Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

100192

China-Japan Friendship Hospital, Beijing

116089

Dalian Municipal Central Hospital, Dalian

121011

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

130061

The First Hospital of Jilin University, Changchun

150001

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

163711

Daqing People's Hospital, Daqing

213004

Changzhou Second People's Hospital, Changzhou

221004

Affiliated Hospital of Xuzhou Medical University, Xuzhou

300122

Tianjin People's Hospital, Tianjin

317000

Taizhou Hospital Of Zhejiang Province, Taizhou

325015

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330008

Nanchang First Hospital, Nanchang

Nanchang Third Hospital, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

410008

The Second Xiangya Hospital Of Central South University, Changsha

434020

Jingzhou Central Hospital, Jingzhou

450052

First Affiliated Hospital of Zhengzhou University, Zhengzhou

716099

Xianyang Hospital of Yan'an University, Xianyang

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER